<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01349309</url>
  </required_header>
  <id_info>
    <org_study_id>GCO # 07-0462</org_study_id>
    <nct_id>NCT01349309</nct_id>
  </id_info>
  <brief_title>The Effect of Prophylactic Swallowing Exercises on Head and Neck Cancer Patients</brief_title>
  <official_title>The Effect of Prophylactic Swallowing Exercises on Head and Neck Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if doing prophylactic or preventative swallowing
      exercises from the start of cancer treatment can improve the ability to swallow when the
      treatment is completed and beyond.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Type: Prospective Randomized Clinical Trial

      Introduction:

      Organ sparing treatment for advanced head and neck cancer can affect the swallowing mechanism
      via fibrosis of the structures responsible for effective and efficient bolus movement from
      the oral cavity and through the pharynx into the esophagus. This fibrosis may result in
      significant impairment of bolus transport. Range of motion exercises for the swallowing
      structures may decrease the fibrotic effects of the radiation treatment and improve
      swallowing outcomes after treatment.

      Intervention:

      Patients who have been diagnosed with head and neck cancer and who will be receiving
      radiation therapy either with or without chemotherapy as cancer treatment will be randomized
      to one of two swallowing treatment protocols. The first protocol will include the initiation
      of intensive swallowing exercises to begin at the start of the cancer treatment. The second
      treatment protocol will include the standard of care which provides swallowing evaluation and
      treatment once symptoms of swallowing dysfunction are experienced by the patient. Patients
      will not be given a choice of swallowing protocol. Those patients randomized to the intensive
      therapy protocol will be required to participate in weekly swallowing therapy sessions either
      in person or over the phone and perform the learned swallowing exercises three times a day.
      In addition, these patients will document their swallowing practice on a daily basis. The
      same investigator will provide all the swallowing treatment assuring that all patients get
      the same treatment approach.

      All patients will fill out a questionnaire about their swallowing ability called the
      Performance Status Scale for Head and Neck Cancer Patients (PSS-H&amp;N). This is a quick,
      clinician rated instrument consisting of three subscales: normalcy of diet, public eating and
      intelligibility of speech. This scale has been proven reliable across raters and sensitive to
      functional differences across a broad spectrum of head and neck cancer patients. This
      questionnaire will be completed at the start of the cancer treatment, at the completion of
      the treatment and at 3, 6, 12 and 24 months after treatment. In addition, the nature of the
      patient's oral intake will be documented by the investigator using the Functional Oral Intake
      Scale (FOIS) which is a seven point scale of diet tolerance. This will be performed at the
      same intervals as the PSS-H&amp;N. Presence or absence of PEG feedings will also be documented at
      these same times. These scales will then be used to compare the swallowing outcomes of the
      patients in the two different treatment protocols.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Performance Status Scale for Head and Neck Cancer Patients and Functional Oral Intake Scale (PSS-H&amp;N).</measure>
    <time_frame>This will be completed at the start of the cancer treatment. Participants will be followed for up to 24 months after treatment.</time_frame>
    <description>This is a quick, clinician rated instrument consisting of three subscales: normalcy of diet, public eating and intelligibility of speech. This scale has been proven reliable across raters and sensitive to functional differences across a broad spectrum of head and neck cancer patients. The Performance Status Scale for Head and Neck Cancer Patients (PSS-H&amp;N) questionnaire will be completed at the start of the cancer treatment, at the completion of the treatment and at 3, 6, 12 and 24 months after treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Performance Status Scale for Head and Neck Cancer Patients and Functional Oral Intake Scale (PSS-H&amp;N).</measure>
    <time_frame>This will be completed at the completion of treatment. Participants will be followed for up to 24 months after treatment.</time_frame>
    <description>This is a quick, clinician rated instrument consisting of three subscales: normalcy of diet, public eating and intelligibility of speech. This scale has been proven reliable across raters and sensitive to functional differences across a broad spectrum of head and neck cancer patients. The Performance Status Scale for Head and Neck Cancer Patients (PSS-H&amp;N) questionnaire will be completed at the start of the cancer treatment, at the completion of the treatment and at 3, 6, 12 and 24 months after treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Performance Status Scale for Head and Neck Cancer Patients and Functional Oral Intake Scale (PSS-H&amp;N).</measure>
    <time_frame>This will be completed at 3 months post treatment. Participants will be followed for up to 24 months after treatment.</time_frame>
    <description>This is a quick, clinician rated instrument consisting of three subscales: normalcy of diet, public eating and intelligibility of speech. This scale has been proven reliable across raters and sensitive to functional differences across a broad spectrum of head and neck cancer patients. The Performance Status Scale for Head and Neck Cancer Patients (PSS-H&amp;N) questionnaire will be completed at the start of the cancer treatment, at the completion of the treatment and at 3, 6, 12 and 24 months after treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Performance Status Scale for Head and Neck Cancer Patients and Functional Oral Intake Scale (PSS-H&amp;N).</measure>
    <time_frame>This will be completed at 6 months post treatment. Participants will be followed for up to 24 months after treatment.</time_frame>
    <description>This is a quick, clinician rated instrument consisting of three subscales: normalcy of diet, public eating and intelligibility of speech. This scale has been proven reliable across raters and sensitive to functional differences across a broad spectrum of head and neck cancer patients. The Performance Status Scale for Head and Neck Cancer Patients (PSS-H&amp;N) questionnaire will be completed at the start of the cancer treatment, at the completion of the treatment and at 3, 6, 12 and 24 months after treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Performance Status Scale for Head and Neck Cancer Patients and Functional Oral Intake Scale (PSS-H&amp;N).</measure>
    <time_frame>This will be completed at 12 months post treatment. Participants will be followed for up to 24 months after treatment.</time_frame>
    <description>This is a quick, clinician rated instrument consisting of three subscales: normalcy of diet, public eating and intelligibility of speech. This scale has been proven reliable across raters and sensitive to functional differences across a broad spectrum of head and neck cancer patients. The Performance Status Scale for Head and Neck Cancer Patients (PSS-H&amp;N) questionnaire will be completed at the start of the cancer treatment, at the completion of the treatment and at 3, 6, 12 and 24 months after treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Performance Status Scale for Head and Neck Cancer Patients and Functional Oral Intake Scale (PSS-H&amp;N).</measure>
    <time_frame>This will be completed at 24 months post treatment. Participants will be followed for up to 24 months after treatment.</time_frame>
    <description>This is a quick, clinician rated instrument consisting of three subscales: normalcy of diet, public eating and intelligibility of speech. This scale has been proven reliable across raters and sensitive to functional differences across a broad spectrum of head and neck cancer patients. The Performance Status Scale for Head and Neck Cancer Patients (PSS-H&amp;N) questionnaire will be completed at the start of the cancer treatment, at the completion of the treatment and at 3, 6, 12 and 24 months after treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional Oral Intake Scale (FOIS)</measure>
    <time_frame>This will be completed at the start of the cancer treatment. Participants will be followed for up to 24 months after treatment.</time_frame>
    <description>A seven point scale of diet tolerance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional Oral Intake Scale (FOIS)</measure>
    <time_frame>This will be completed at the completion of treatment. Participants will be followed for up to 24 months after treatment.</time_frame>
    <description>A seven point scale of diet tolerance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional Oral Intake Scale (FOIS)</measure>
    <time_frame>This will be completed at 3 post treatment. Participants will be followed for up to 24 months after treatment.</time_frame>
    <description>A seven point scale of diet tolerance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional Oral Intake Scale (FOIS)</measure>
    <time_frame>This will be completed at 6 months post treatment. Participants will be followed for up to 24 months after treatment.</time_frame>
    <description>A seven point scale of diet tolerance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional Oral Intake Scale (FOIS)</measure>
    <time_frame>This will be completed at 12 months post treatment. Participants will be followed for up to 24 months after treatment.</time_frame>
    <description>A seven point scale of diet tolerance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional Oral Intake Scale (FOIS)</measure>
    <time_frame>This will be completed at 24 months post treatment. Participants will be followed for up to 24 months after treatment.</time_frame>
    <description>A seven point scale of diet tolerance.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Dysphagia</condition>
  <arm_group>
    <arm_group_label>Swallowing Exercise Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Swallowing Exercise Group: This arm will undergo the protocol that involves intensive swallowing exercises to begin at the start of the cancer treatment. Those patients randomized to the intensive therapy protocol will be required to participate in weekly swallowing therapy sessions either in person or over the phone and perform the learned swallowing exercises three times a day. In addition, these patients will document their swallowing practice on a daily basis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control Arm: This arm will receive the standard of care which provides swallowing evaluation and treatment once symptoms of swallowing dysfunction are experienced by the patient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Swallowing Exercise Group</intervention_name>
    <description>Swallowing Exercises
Perform each exercise 10 times. Do these 3 times a day. Vary the order of the exercises.
Effortful Swallow: As you swallow squeeze hard with all your muscles. (Can do with water or without)
Super Supraglottic Swallow:
Inhale and hold your breath very tightly, bearing down. Keep holding your breath and bearing down as you swallow. Cough when you are finished. (Can do with water or without)
Tongue Hold Maneuver:
Gently hold your tongue in between your front teeth and swallow your saliva.
Tongue Retraction:
Pull the back of your tongue to the back of your mouth and hold.
Mendelsohn Maneuver:
Swallow your saliva and pay attention to your neck as you swallow. Try to feel that something (your Adam's apple of voice box) lifts and lowers as you swallow. Now, when you swallow and you feel something lift as you swallow don't let it drop. Hold it with your muscles for several seconds.</description>
    <arm_group_label>Swallowing Exercise Group</arm_group_label>
    <other_name>Prophylactic Swallowing Exercises</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patient diagnosed with head and neck cancer who will be receiving radiation therapy
             either alone of with chemotherapy as their treatment modality.

        Exclusion criteria:

          -  Patients with a history of neurologic disease

          -  Patients with previous head and neck cancer or surgical or radiation treatment to the
             head and neck region

          -  Patients taking medication that might effect their swallowing function

          -  Patients with gastroenterologic dysfunction

          -  Patients who have previously undergone swallowing therapy

          -  Patients with cognitive impairments that limit their ability to follow and comply with
             multi-step commands
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tamar Kotz, MS, CCC, SLP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lee NY, de Arruda FF, Puri DR, Wolden SL, Narayana A, Mechalakos J, Venkatraman ES, Kraus D, Shaha A, Shah JP, Pfister DG, Zelefsky MJ. A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):966-74.</citation>
    <PMID>17145527</PMID>
  </reference>
  <reference>
    <citation>El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. J Clin Oncol. 1996 Mar;14(3):838-47.</citation>
    <PMID>8622032</PMID>
  </reference>
  <reference>
    <citation>Pignon JP, Bourhis J, Domenge C, Design√© L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000 Mar 18;355(9208):949-55.</citation>
    <PMID>10768432</PMID>
  </reference>
  <reference>
    <citation>Mendenhall WM, Amdur RJ, Stringer SP, Villaret DB, Cassisi NJ. Radiation therapy for squamous cell carcinoma of the tonsillar region: a preferred alternative to surgery? J Clin Oncol. 2000 Jun;18(11):2219-25.</citation>
    <PMID>10829041</PMID>
  </reference>
  <reference>
    <citation>Kramer S, Gelber RD, Snow JB, Marcial VA, Lowry LD, Davis LW, Chandler R. Combined radiation therapy and surgery in the management of advanced head and neck cancer: final report of study 73-03 of the Radiation Therapy Oncology Group. Head Neck Surg. 1987 Sep-Oct;10(1):19-30.</citation>
    <PMID>3449477</PMID>
  </reference>
  <reference>
    <citation>Robbins KT. Barriers to winning the battle with head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):4-5.</citation>
    <PMID>12007934</PMID>
  </reference>
  <reference>
    <citation>Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Oudinot P, Bertrand P. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999 Dec 15;91(24):2081-6.</citation>
    <PMID>10601378</PMID>
  </reference>
  <reference>
    <citation>Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V, George SL, Huang AT, Prosnitz LR. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998 Jun 18;338(25):1798-804.</citation>
    <PMID>9632446</PMID>
  </reference>
  <reference>
    <citation>Vokes EE, Stenson K, Rosen FR, Kies MS, Rademaker AW, Witt ME, Brockstein BE, List MA, Fung BB, Portugal L, Mittal BB, Pelzer H, Weichselbaum RR, Haraf DJ. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol. 2003 Jan 15;21(2):320-6.</citation>
    <PMID>12525525</PMID>
  </reference>
  <reference>
    <citation>Newman LA, Vieira F, Schwiezer V, Samant S, Murry T, Woodson G, Kumar P, Robbins KT. Eating and weight changes following chemoradiation therapy for advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 1998 May;124(5):589-92.</citation>
    <PMID>9604988</PMID>
  </reference>
  <reference>
    <citation>Adelstein DJ, Saxton JP, Lavertu P, Rybicki LA, Esclamado RM, Wood BG, Strome M, Carroll MA. Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy. J Clin Oncol. 2002 Mar 1;20(5):1405-10.</citation>
    <PMID>11870186</PMID>
  </reference>
  <reference>
    <citation>Smith RV, Kotz T, Beitler JJ, Wadler S. Long-term swallowing problems after organ preservation therapy with concomitant radiation therapy and intravenous hydroxyurea: initial results. Arch Otolaryngol Head Neck Surg. 2000 Mar;126(3):384-9.</citation>
    <PMID>10722013</PMID>
  </reference>
  <reference>
    <citation>Hutcheson KA, Barringer DA, Rosenthal DI, May AH, Roberts DB, Lewin JS. Swallowing outcomes after radiotherapy for laryngeal carcinoma. Arch Otolaryngol Head Neck Surg. 2008 Feb;134(2):178-83. doi: 10.1001/archoto.2007.33.</citation>
    <PMID>18283161</PMID>
  </reference>
  <reference>
    <citation>Bleier BS, Levine MS, Mick R, Rubesin SE, Sack SZ, McKinney K, Mirza N. Dysphagia after chemoradiation: analysis by modified barium swallow. Ann Otol Rhinol Laryngol. 2007 Nov;116(11):837-41.</citation>
    <PMID>18074669</PMID>
  </reference>
  <reference>
    <citation>Murry T, Madasu R, Martin A, Robbins KT. Acute and chronic changes in swallowing and quality of life following intraarterial chemoradiation for organ preservation in patients with advanced head and neck cancer. Head Neck. 1998 Jan;20(1):31-7.</citation>
    <PMID>9464950</PMID>
  </reference>
  <reference>
    <citation>Pauloski BR, Logemann JA. Impact of tongue base and posterior pharyngeal wall biomechanics on pharyngeal clearance in irradiated postsurgical oral and oropharyngeal cancer patients. Head Neck. 2000 Mar;22(2):120-31.</citation>
    <PMID>10679899</PMID>
  </reference>
  <reference>
    <citation>Kotz T, Costello R, Li Y, Posner MR. Swallowing dysfunction after chemoradiation for advanced squamous cell carcinoma of the head and neck. Head Neck. 2004 Apr;26(4):365-72.</citation>
    <PMID>15054740</PMID>
  </reference>
  <reference>
    <citation>Eisbruch A, Lyden T, Bradford CR, Dawson LA, Haxer MJ, Miller AE, Teknos TN, Chepeha DB, Hogikyan ND, Terrell JE, Wolf GT. Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):23-8.</citation>
    <PMID>12007937</PMID>
  </reference>
  <reference>
    <citation>Lazarus CL, Logemann JA, Pauloski BR, Colangelo LA, Kahrilas PJ, Mittal BB, Pierce M. Swallowing disorders in head and neck cancer patients treated with radiotherapy and adjuvant chemotherapy. Laryngoscope. 1996 Sep;106(9 Pt 1):1157-66.</citation>
    <PMID>8822723</PMID>
  </reference>
  <reference>
    <citation>Lazarus CL, Logemann JA, Pauloski BR, Rademaker AW, Larson CR, Mittal BB, Pierce M. Swallowing and tongue function following treatment for oral and oropharyngeal cancer. J Speech Lang Hear Res. 2000 Aug;43(4):1011-23.</citation>
    <PMID>11386468</PMID>
  </reference>
  <reference>
    <citation>Kotz T, Abraham S, Beitler JJ, Wadler S, Smith RV. Pharyngeal transport dysfunction consequent to an organ-sparing protocol. Arch Otolaryngol Head Neck Surg. 1999 Apr;125(4):410-3.</citation>
    <PMID>10208678</PMID>
  </reference>
  <reference>
    <citation>Logemann JA, Pauloski BR, Rademaker AW, Colangelo LA. Super-supraglottic swallow in irradiated head and neck cancer patients. Head Neck. 1997 Sep;19(6):535-40.</citation>
    <PMID>9278762</PMID>
  </reference>
  <reference>
    <citation>Lazarus C, Logemann JA, Song CW, Rademaker AW, Kahrilas PJ. Effects of voluntary maneuvers on tongue base function for swallowing. Folia Phoniatr Logop. 2002 Jul-Aug;54(4):171-6.</citation>
    <PMID>12169803</PMID>
  </reference>
  <reference>
    <citation>Lazarus C, Logemann JA, Gibbons P. Effects of maneuvers on swallowing function in a dysphagic oral cancer patient. Head Neck. 1993 Sep-Oct;15(5):419-24.</citation>
    <PMID>8407314</PMID>
  </reference>
  <reference>
    <citation>Kulbersh BD, Rosenthal EL, McGrew BM, Duncan RD, McColloch NL, Carroll WR, Magnuson JS. Pretreatment, preoperative swallowing exercises may improve dysphagia quality of life. Laryngoscope. 2006 Jun;116(6):883-6.</citation>
    <PMID>16735913</PMID>
  </reference>
  <reference>
    <citation>Carroll WR, Locher JL, Canon CL, Bohannon IA, McColloch NL, Magnuson JS. Pretreatment swallowing exercises improve swallow function after chemoradiation. Laryngoscope. 2008 Jan;118(1):39-43.</citation>
    <PMID>17989581</PMID>
  </reference>
  <results_reference>
    <citation>Kotz T, Federman AD, Kao J, Milman L, Packer S, Lopez-Prieto C, Forsythe K, Genden EM. Prophylactic swallowing exercises in patients with head and neck cancer undergoing chemoradiation: a randomized trial. Arch Otolaryngol Head Neck Surg. 2012 Apr;138(4):376-82. doi: 10.1001/archoto.2012.187.</citation>
    <PMID>22508621</PMID>
  </results_reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2011</study_first_submitted>
  <study_first_submitted_qc>May 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2011</study_first_posted>
  <last_update_submitted>December 3, 2015</last_update_submitted>
  <last_update_submitted_qc>December 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prophylactic Swallowing Exercises</keyword>
  <keyword>Head and Neck Cancer</keyword>
  <keyword>Dysphagia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Deglutition Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

